
Immuneering Corporation
Immuneering Corporation (IMRX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IMRX · as of Jun 8, 2026
Key Statistics
Explore Immuneering Corporation Data
imrx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 63.6%
The IMRX analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $12.00, representing +205.34% upside from the current price of $3.93.
Competitors & Peers
imrx competitorsStock Performance
Full HistoryAbout Immuneering Corporation
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development effort…
what is immuneering corporation · imrx stock overview · immuneering corporation company profile · who is immuneering corporation ceo · imrx NASDAQ · immuneering corporation headquarters · immuneering corporation business segments
About Stock Overview & Key Data
Immuneering Corporation (IMRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 30, 2021. As of the latest trading session, IMRX stock price is $3.93, with a market capitalization of $142.7M. The stock has returned +81.11% over the past 12 months and -40.27% year-to-date.
According to 11 Wall Street analysts, the consensus rating for Immuneering Corporation stock is Buy, with an average 12-month price target of $12.00. In fiscal year 2025, Immuneering Corporation reported revenue of — and net income of -$56.0M. For detailed data — including Immuneering Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Immuneering Corporation (IMRX) stock price is $3.93. The stock is traded on NASDAQ under the ticker symbol IMRX. The 52-week range is $1.66 – $10.08.